| Literature DB >> 23594436 |
Bledar Daka1, Thord Rosen, Per Anders Jansson, Charlotte A Larsson, Lennart Råstam, Ulf Lindblad.
Abstract
BACKGROUND: The aim of this study was to investigate the association of sex hormone-binding globulin (SHBG) and hypertension in a Swedish population.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23594436 PMCID: PMC3663757 DOI: 10.1186/1471-2261-13-30
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Phenotypical characterisation of sex hormone-binding globulin in a Swedish population of men and women
| | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | ||||||||||
| SHBG | 33±14 | 17.8 | 26.7 | 35.1 | 50.8 | | 55±31 | 26.2 | 41.1 | 55.6 | 92.6 | |
| Age | 47.8±11.8 | 42.2 | 45.6 | 48.8 | 54.4 | <0.001 | 47.7±11.7 | 46.9 | 47.3 | 49.0 | 47.7 | 0.033 |
| BMI | 26.9±3.6 | 28.9 | 27.3 | 26.5 | 24.9 | <0.001 | 26.8±5.3 | 30.1 | 27.2 | 26.5 | 24.9 | <0.001 |
| Fasting insulin | 6.7±5.2 | 8.9 | 7.0 | 6.2 | 4.9 | <0.001 | 6.2±4.4 | 8.5 | 6.2 | 5.1 | 4.7 | <0.001 |
| Fasting glucose | 5.5±1.1 | 5.8 | 5.7 | 5.5 | 5.4 | <0.001 | 5.3±1.1 | 5.7 | 5.4 | 5.1 | 5.1 | <0.001 |
| HOMA-IR | 1.7±1.6 | 2.3 | 1.8 | 1.5 | 1.1 | <0.001 | 1.5±1.3 | 2.2 | 1.5 | 1.2 | 1.1 | <0.001 |
| Hs-CRP | 2.4±5.8 | 3.0 | 2.3 | 1.9 | 3.3 | 0.038 | 2.7±4.6 | 4.1 | 2.5 | 2.2 | 2.3 | 0.097 |
| LDL | 3.4±0.9 | 3.4 | 3.4 | 3.4 | 3.3 | 0.327 | 3.1±0.9 | 3.2 | 3.1 | 3.2 | 3.2 | 0.287 |
| HDL | 1.2±0.3 | 1.1 | 1.2 | 1.2 | 1.3 | <0.001 | 1.4±0.3 | 1.2 | 1.4 | 1.5 | 1.5 | <0.001 |
| Triglycerides | 1.5±0.9 | 1.9 | 1.5 | 1.3 | 1.1 | <0.001 | 1.2±0.6 | 1.4 | 1.1 | 1.0 | 1.1 | 0.004 |
| Systolic BP | 123±16 | 126 | 124 | 123 | 123 | <0.001 | 119±18 | 123 | 118 | 117 | 119 | 0.008 |
| Diastolic BP | 72±10 | 73.8 | 71.7 | 71.8 | 70.6 | <0.001 | 69±10 | 70.0 | 68.4 | 67.8 | 68.2 | 0.007 |
| Total Testosterone | 14.3±4.4 | 11.2 | 13.4 | 15.2 | 17.5 | <0.001 | 1.3±1.3 | 1.3 | 1.2 | 1.2 | 1.3 | 0.853 |
| Oestradiol | 127±56 | 125 | 128 | 124 | 132 | 0.026 | 320±396 | 255 | 328 | 337 | 363 | <0.001 |
| FAI | 48.5±17.3 | 64.5 | 50.5 | 43.4 | 35.3 | <0.001 | 3.1±5.8 | 5.7 | 2.9 | 2.4 | 1.4 | <0.001 |
SHBG= sex hormone-binding globulin, Q1 is the lowest quartile and Q4 is the highest. BMI=Body mass index, HOMA-IR= homeostatic model assessment insulin resistance, hs-CRP=high sensitive c-reactive protein, LDL=low density lipoprotein, HDL=high density protein, BP= blood pressure, FAI=free androgen index.
General linear models to estimate mean values and differences between quartiles were used. The significance was estimated with p-value.
The association between total testosterone, SHBG, oestradiol, free testosterone, respectively, and blood pressure in men and women
| | ||||||||
|---|---|---|---|---|---|---|---|---|
| | ||||||||
| Total testosterone | -0.136 | <0.001 | -0.121 | <0.001 | -0.011 | 0.470 | -0.013 | 0.638 |
| Sex hormone-binding globulin | -0.114 | <0.001 | -0.143 | <0.001 | -0.031 | 0.193 | -0.055 | 0.041 |
| Oestradiol | -0.014 | 0.560 | 0.022 | 0.408 | -0.035 | 0.144 | -0.057 | 0.036 |
| Free testosterone | -0.051 | 0.119 | -0.051 | 0.154 | 0.009 | 0.698 | 0.016 | 0.574 |
| Total testosterone | -0.114 | <0.001 | -0.098 | 0.001 | -0.008 | 0.873 | -0.018 | 0.576 |
| Sex hormone-binding globulin | -0.083 | 0.005 | -0.117 | <0.001 | 0.020 | 0.685 | -0.018 | 0.610 |
| Oestradiol | -0.019 | 0.440 | 0.017 | 0.530 | -0.036 | 0.121 | -0.025 | 0.461 |
| Free testosterone | -0.039 | 0.243 | -0.035 | 0.328 | -0.016 | 0.570 | -0.001 | 0.988 |
| Total testosterone | -0.111 | <0.001 | -0.089 | 0.002 | -0.002 | 0.932 | -0.014 | 0.468 |
| Sex hormone-binding globulin | -0.078 | 0.009 | -0.105 | 0.001 | 0.043 | 0.146 | 0.004 | 0.908 |
| Oestradiol | -0.026 | 0.295 | 0.000 | 0.999 | -0.008 | 0.768 | -0.020 | 0.556 |
| Free testosterone | -0.034 | 0.348 | -0.033 | 0.363 | -0.019 | 0.487 | -0.006 | 0.855 |
| Total testosterone | -0.123 | <0.001 | -0.097 | 0.001 | 0.005 | 0.846 | -0.008 | 0.814 |
| Sex hormone-binding globulin | -0.093 | 0.001 | -0.113 | <0.001 | 0.041 | 0.166 | 0.013 | 0.718 |
| Oestradiol | -0.028 | 0.277 | 0.000 | 0.994 | -0.004 | 0.902 | -0.017 | 0.611 |
| Free testosterone | -0.035 | 0.307 | -0.032 | 0.878 | -0.014 | 0.620 | -0.005 | 0.876 |
BMI: Body mass index, Tg: triglycerides, HOMA-IR: homeostatic model assessment insulin resistance, HDL: high density lipoprotein, CRP: c-reactive protein, β: regressions coefficient, p: p value. Linear regression analysis is used to investigate the association between hormonal levels and blood pressure. All subjects with known hypertension (271) were excluded from the analyses.
Figure 1Comparison of serum concentrations of sex hormone-binding globulin (y-axis) between different blood pressure categories. JNC7 blood pressure categories; Opt=normal optimal BP <120/80 mm Hg, Nor= normal BP <130/85 mm Hg, Hnor= normal high BP <140/90 mm Hg, Unst= unstable blood pressure Hypertension was defined as known documented diagnosis for high blood pressure, or by three consecutive BP reading ≥140/90 mm Hg (systolic and/or diastolic). When the BP exceeded these limits only once or twice the BP was categorized as unstable.
Multivariate analyses of OR for hypertension associated with quartiles of sex hormone-binding globulin in women and men, respectively
| All | Q 1 vs 4 | 2.2 | 1.24-3.75 | 0.007 | All | 4.2 | 2.45-7.06 | <0.001 |
| | Q 2 vs 4 | 1.7 | 1.05-2.78 | 0.031 | | 2.3 | 1.31-3.91 | 0.004 |
| | Q 3 vs 4 | 1.2 | 0.72-1.82 | 0.549 | | 1.9 | 1.12-3.26 | 0.017 |
| <50 y | Q 1 vs 4 | 1.9 | 0.76-4.68 | 0.174 | <50 y | 2.8 | 1.14-7.22 | 0.025 |
| | Q 2 vs 4 | 1.6 | 0.61-4.24 | 0.333 | | 1.7 | 0.61-4.49 | 0.317 |
| | Q 3 vs 4 | 0.7 | 0.25-2.18 | 0.582 | | 1.6 | 0.53-4.98 | 0.403 |
| >50 y | Q 1 vs 4 | 2.1 | 0.99-4.66 | 0.053 | ≥50 y | 4.8 | 2.61-8.88 | <0.001 |
| | Q 2 vs 4 | 1.6 | 0.92-2.78 | 0.095 | | 2.3 | 1.21-4.22 | 0.010 |
| | Q 3 vs 4 | 1.2 | 0.70-1.95 | 0.546 | | 2.1 | 1.17-3.82 | 0.013 |
| All | Q 1 vs 4 | 1.5 | 0.82-2.67 | 0.193 | ≥50 y | 3.1 | 1.54-6.04 | 0.001 |
| | Q 2 vs 4 | 1.3 | 0.81-2.22 | 0.250 | | 1.9 | 1.00-3.79 | 0.049 |
| | Q 3 vs 4 | 1.0 | 0.63-1.61 | 0.982 | | 2.2 | 1.20-4.15 | 0.012 |
| All | Q 1 vs 4 | 1.5 | 0.78-2.70 | 0.235 | ≥50 y | 3.0 | 1.47-6.33 | 0.003 |
| | Q 2 vs 4 | 1.4 | 0.81-2.22 | 0.217 | | 2.1 | 1.04-4.09 | 0.038 |
| | Q 3 vs 4 | 1.0 | 0.59-1.57 | 0.867 | | 2.1 | 1.12-4.04 | 0.021 |
| All | Q 1 vs 4 | 1.8 | 0.96-3.27 | 0.067 | ≥50 y | 2.7 | 1.33-5.60 | 0.006 |
| | Q 2 vs 4 | 1.4 | 0.83-2.43 | 0.202 | | 1.9 | 0.95-3.67 | 0.070 |
| Q 3 vs 4 | 1.1 | 0.67-1.79 | 0.721 | 1.8 | 0.97-3.41 | 0.061 | ||
BMI: Body mass index, Tg: triglycerides, HOMA-IR: homeostatic model assessment insulin resistance, LDL: Low density lipoprotein, CRP: c-reactive protein, HRT: hormone replacement therapy, OR: odds ration for hypertension, p: p value. Logistic regression analysis is used to investigate the association between hormonal levels and hypertension. Possible confounders were taken into consideration in different models stepwise.
Association between hypertension and sex hormone-binding globulin when major risk factors for hypertension are considered
| | All | 1.352 | <0.001 | 3.9 | | 1.299 | <0.001 | 3.7 | |
| | | 0.298 | 0.004 | 1.3 | | 0.376 | 0.002 | 1.5 | |
| | | 0.060 | 0.497 | 1.1 | | 0.347 | 0.002 | 1.4 | |
| | | -0.194 | 0.061 | 0.8 | | -0.297 | 0.027 | 0.7 | |
| | <50 | 0.619 | <0.001 | 1.9 | | 0.967 | <0.001 | 2.6 | |
| | | 0.298 | 0.004 | 1.3 | | 0.532 | 0.012 | 1.7 | |
| | | 0.049 | 0.497 | 1.1 | | 0.018 | 0.927 | 1.0 | |
| | | -0.164 | 0.061 | 0.8 | | -0.103 | 0.698 | 0.9 | |
| | ≥50 | 0.882 | <0.001 | 2.4 | | 0.723 | <0.001 | 2.1 | |
| | | 0.298 | 0.004 | 1.3 | | 0.382 | 0.012 | 1.5 | |
| | | 0.072 | 0.491 | 1.1 | | 0.538 | 0.001 | 1.7 | |
| -0.210 | 0.063 | 0.8 | -0.333 | 0.033 | 0.7 |
BMI: Body mass index, HOMA-IR: homeostatic model assessment insulin resistance, SHBG: sex hormone-binding globulin, β: regressions coefficient, p: p value, Exp: the odds change for hypertension for increasing with 1 standard deviation of variable. Age, BMI, HOMA-IR are standardised in order to compare the impact in hypertension. Logistic regression analysis is used to rank the strength of the association. All women with hormonal therapy are excluded from the analyses. Every considered variable is standardised. The purpose was to rank the strength of the association with hypertension for each variable and the value of β decide the strength of the association. We standardised the variables in consideration by the formula SV=V/SD, where SV is the standardised variable. V is the value of the variable and SD is the standard deviation.